Veeva's OpenData and Network Drive Enhanced Engagement for Boehringer Ingelheim
In a significant move towards enhancing customer engagement in the biopharma sector, Veeva Systems (NYSE: VEEV) has declared that Boehringer Ingelheim, a prominent player among the top 20 biopharmaceutical companies, is adopting Veeva OpenData and Veeva Network to streamline and standardize its customer data internationally. This initiative represents a critical advancement in how biopharma organizations manage customer relationships and leverage data-driven insights in today's dynamic market environment.
With the integration of Veeva OpenData, Boehringer Ingelheim aims to furnish its teams with reliable and comprehensive customer reference data across more than 100 countries. This reliable data source is expected to empower the company's field staff to connect with healthcare professionals (HCPs) more effectively, providing them with pertinent information that is essential for informed decision-making. Uday Bose, who spearheads human pharma global customer experience excellence and business steering at Boehringer Ingelheim, expressed his confidence in this partnership, noting that globally harmonized data is crucial for strengthening customer engagement. He highlights the potential of this initiative to pave the way for future applications of artificial intelligence in the organization.
Boehringer Ingelheim's transition to this unified data strategy, which consolidates various data sources into a single, comprehensive platform, is set to simplify data management significantly. By standardizing their data processes, the company anticipates improved speed and quality in accessing consistent customer data, fostering better collaboration across different teams and regions. This degree of integration not only enhances inter-team communication but also enhances overall operational efficiency.
Additionally, the collaboration between Boehringer Ingelheim and Veeva signifies a move towards a seamless migration to Veeva Vault Customer Relationship Management (CRM) software. By harnessing the native integrations provided by OpenData and Veeva Network, Boehringer Ingelheim can streamline its transition and firmly establish a foundation for future commercial successes based on data.
Kilian Weiss, senior vice president at Veeva, pointed out that Boehringer Ingelheim's focus on connected software and data positions them well for ongoing commercial excellence. By adopting a holistic software solution that integrates Vault CRM, OpenData, and Network, the company aims to enhance HCP engagement and drive innovations centered around artificial intelligence at scale. This systemic approach allows for more effective commercial execution, which is becoming increasingly vital in the competitive biopharma landscape.
Veeva OpenData, as part of the Veeva Data Cloud, enhances its suite of tools that also includes Veeva Link, Veeva Compass, and Veeva CRM Pulse. Each of these elements contributes to a broader strategy aimed at leveraging data connectivity not only for facilitating sales and marketing initiatives but also for medical teams engaged in important healthcare conversations.
Established as a leader in cloud software solutions tailored for the life sciences sector, Veeva Systems continues to innovate and enhance its offerings. The partnership with Boehringer Ingelheim showcases its commitment to aiding biopharma companies in transcending traditional data management approaches and embracing a future defined by streamlined processes and data-driven decisions. As Veeva serves a diverse clientele—including both large pharmaceutical enterprises and emerging biotech companies—it also emphasizes its role as a public benefit corporation, balancing the interests of various stakeholders within the industry.
For more information about how Veeva Systems is transforming biopharma data management, you can visit www.veeva.com. The combination of Veeva OpenData and Veeva Network essentially sets the stage for Boehringer Ingelheim to engage with healthcare professionals in a more structured and impactful manner, ultimately aiming for enhanced patient outcomes and a promising future in AI applications.
This strategic move is a testament to Boehringer Ingelheim’s commitment to innovation, efficiency, and excellence in customer experience, ensuring that they remain competitive in an ever-evolving landscape. Nevertheless, as with all innovative initiatives, both companies acknowledge the inherent risks and uncertainties involved as they navigate through this transformative process. Future updates and developments will undoubtedly shed light on the full impact of this initiative on the biopharma industry at large.
With the integration of Veeva OpenData, Boehringer Ingelheim aims to furnish its teams with reliable and comprehensive customer reference data across more than 100 countries. This reliable data source is expected to empower the company's field staff to connect with healthcare professionals (HCPs) more effectively, providing them with pertinent information that is essential for informed decision-making. Uday Bose, who spearheads human pharma global customer experience excellence and business steering at Boehringer Ingelheim, expressed his confidence in this partnership, noting that globally harmonized data is crucial for strengthening customer engagement. He highlights the potential of this initiative to pave the way for future applications of artificial intelligence in the organization.
Boehringer Ingelheim's transition to this unified data strategy, which consolidates various data sources into a single, comprehensive platform, is set to simplify data management significantly. By standardizing their data processes, the company anticipates improved speed and quality in accessing consistent customer data, fostering better collaboration across different teams and regions. This degree of integration not only enhances inter-team communication but also enhances overall operational efficiency.
Additionally, the collaboration between Boehringer Ingelheim and Veeva signifies a move towards a seamless migration to Veeva Vault Customer Relationship Management (CRM) software. By harnessing the native integrations provided by OpenData and Veeva Network, Boehringer Ingelheim can streamline its transition and firmly establish a foundation for future commercial successes based on data.
Kilian Weiss, senior vice president at Veeva, pointed out that Boehringer Ingelheim's focus on connected software and data positions them well for ongoing commercial excellence. By adopting a holistic software solution that integrates Vault CRM, OpenData, and Network, the company aims to enhance HCP engagement and drive innovations centered around artificial intelligence at scale. This systemic approach allows for more effective commercial execution, which is becoming increasingly vital in the competitive biopharma landscape.
Veeva OpenData, as part of the Veeva Data Cloud, enhances its suite of tools that also includes Veeva Link, Veeva Compass, and Veeva CRM Pulse. Each of these elements contributes to a broader strategy aimed at leveraging data connectivity not only for facilitating sales and marketing initiatives but also for medical teams engaged in important healthcare conversations.
Established as a leader in cloud software solutions tailored for the life sciences sector, Veeva Systems continues to innovate and enhance its offerings. The partnership with Boehringer Ingelheim showcases its commitment to aiding biopharma companies in transcending traditional data management approaches and embracing a future defined by streamlined processes and data-driven decisions. As Veeva serves a diverse clientele—including both large pharmaceutical enterprises and emerging biotech companies—it also emphasizes its role as a public benefit corporation, balancing the interests of various stakeholders within the industry.
For more information about how Veeva Systems is transforming biopharma data management, you can visit www.veeva.com. The combination of Veeva OpenData and Veeva Network essentially sets the stage for Boehringer Ingelheim to engage with healthcare professionals in a more structured and impactful manner, ultimately aiming for enhanced patient outcomes and a promising future in AI applications.
This strategic move is a testament to Boehringer Ingelheim’s commitment to innovation, efficiency, and excellence in customer experience, ensuring that they remain competitive in an ever-evolving landscape. Nevertheless, as with all innovative initiatives, both companies acknowledge the inherent risks and uncertainties involved as they navigate through this transformative process. Future updates and developments will undoubtedly shed light on the full impact of this initiative on the biopharma industry at large.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.